Research

How to read ClinicalTrials.gov phase labels: what Phase 1, 2 and 3 do-and do not-mean

2026-09-24 · 5 min read

Reader note: This is a guide to reading study records, not medical advice or a recommendation to join any trial. A phase label is one part of a record. Check the current official record, its eligibility criteria and contacts, and discuss personal medical questions with an appropriate health professional.

Start with the label, then read the study

ClinicalTrials.gov can list a study phase for certain drug and biologic studies. The label tells readers where a study sits in a development program; it does not settle the question a particular study is asking. Read the record's purpose, intervention, eligibility, recruitment status, outcomes and posted results separately.

The familiar Phase 1, Phase 2 and Phase 3 sequence comes from FDA's drug-development framework. Individual studies can differ in participants, size, duration and design. Some studies use more than one phase label, and records for behavioral, device and some other studies can say Not Applicable. A missing or Not Applicable phase is not evidence that a study is lower quality, safe, ineffective or unregulated.

Phase 1: early research in people

FDA describes Phase 1 as the initial stage of clinical research in people. These studies commonly examine dose, short-term adverse effects and how a drug interacts with the body. They are often small and may involve healthy volunteers, although some conditions call for enrolling people with the condition.

What the label can support: the study is early in the drug-development sequence and is designed to gather information that helps later research.

What it cannot support: that a dose is safe for you, that the intervention works for a condition, that a study is open to the public, or that a participant will receive the investigational intervention.

Phase 2: a focused question with continuing safety follow-up

FDA says Phase 2 studies usually enroll people with the condition being studied and gather further safety information while examining whether the drug may work for that condition. FDA also cautions that these studies are typically not large enough to show whether a drug will be beneficial.

What the label can support: the protocol is asking a more focused question in the relevant population, while safety assessment continues.

What it cannot support: that benefit has been demonstrated, that results will apply to everyone with the condition, or that the study is a substitute for clinical care.

Phase 3: larger studies still answer specific questions

FDA describes Phase 3 studies as larger studies that gather more information about safety and effectiveness, including across populations, doses or combinations. Their scale can help detect effects that smaller studies may miss, including less common adverse reactions. The record still needs to be read for its actual design, comparison group, outcome measures and results status.

What the label can support: the study is later-stage research designed to address specified protocol questions with more participants.

What it cannot support: that FDA has approved the product, that every endpoint was met, that the balance of benefits and risks is favorable for a particular person, or that the study is currently recruiting.

Phase 4 and the separate question of approval

FDA describes Phase 4 as post-market research after FDA approval. That definition does not turn a Phase 1, 2 or 3 listing into approval. FDA approval is a separate regulatory decision based on its review of submitted evidence for an intended population and use. A ClinicalTrials.gov listing itself is also not an FDA endorsement of a study, sponsor, product or result.

A short record-reading checklist

Before drawing a conclusion from a phase label, check:

whether the study is drug-related and what phase or phases the record actually lists;
the study's purpose, intervention, design and primary outcomes;
current recruitment status, locations and Last Update Posted date;
eligibility and exclusion criteria, which only the study team can apply;
whether results are posted and what they report; and
the official regulatory status of any product, separately from the registry listing.

Phase labels are useful orientation, not a scorecard. The specific protocol and current official record are the evidence readers need for any study-specific conclusion.